Skip to the answer

Adalimumab Injection

Adalimumab Injection is a TNF blocker given under the skin to treat several inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.

Brand names HumiraAmjevitaYuflymaHadlimaYusimry +7 more
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 3 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Adalimumab Injection at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Adalimumab is a long-established biologic for rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis and other inflammatory conditions, working by blocking TNF-alpha, a protein that drives inflammation, and it is often the first biologic tried when standard treatments fall short, with Humira now joined by several biosimilars (near-identical, usually lower-cost versions). Most people tolerate it well. What they notice is stinging, redness or itching where they inject, and more colds and sinus infections. It carries a boxed warning for serious infections, including tuberculosis (TB), and for certain cancers, so expect a TB test before starting and call your doctor promptly for fever or any sign of infection.

Clinical pearls

  • Store it in the refrigerator, never frozen, and let it reach room temperature before injecting to ease the sting.
  • Live vaccines are off limits while on it, so get your vaccines up to date before the first dose.
  • Report a lasting cough, night sweats or weight loss, since TB can surface even after a negative screening test.
  • If you use it during pregnancy, tell your baby’s pediatrician, because the infant’s live vaccines may need careful timing.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Adalimumab raises the risk of serious infections that can lead to hospitalization or death, and of certain cancers.

Infections include tuberculosis (including reactivation of past TB), fungal infections and bacterial or viral infections. People also taking steroids or methotrexate are most affected. Your doctor should test you for TB first and watch you closely during and after treatment. Stop and call your doctor if you develop a serious infection.

Lymphoma and other cancers, some fatal, have been reported in children and teens on TNF blockers. A rare, aggressive cancer called hepatosplenic T-cell lymphoma has occurred mostly in teen and young adult males with Crohn's disease or ulcerative colitis who were also taking azathioprine or 6-mercaptopurine.

Read the full warning on DailyMed →
How you get itPrescription only
Comes asInjection
Earliest FDA record2002
Companies listing it with the FDA2
FDA label last updatedJan 8, 2026
FDA’s strongest warning (boxed)Yes, read the warning

Patient information guide A plain-language walkthrough of Adalimumab Injection, written from its FDA label.

What Adalimumab Injection is used for

▾

Adalimumab Injection is a TNF blocker used for these conditions:

  • Rheumatoid arthritis in adults
  • Polyarticular juvenile idiopathic arthritis, age 2 and older
  • Psoriatic arthritis in adults
  • Ankylosing spondylitis in adults
  • Crohn's disease in adults and children 6 and older
  • Ulcerative colitis in adults
  • Moderate to severe chronic plaque psoriasis in adults
  • Hidradenitis suppurativa in adults (Yuflyma is also established for ages 12 and older)
  • Non-infectious intermediate, posterior and panuveitis in adults (Yuflyma is also established for children 2 and older)

In ulcerative colitis, effectiveness has not been established in people who lost response to or could not tolerate other TNF blockers.

How Adalimumab Injection works

▾

Adalimumab binds to TNF-alpha, a natural protein involved in inflammation, and blocks it from attaching to its receptors on cells. High TNF levels play a role in the joint inflammation and damage of arthritis and are also found in psoriasis plaques. Blocking TNF helps reduce that inflammation.

Adalimumab Injection dosage

▾

Adalimumab Injection is injected under the skin, usually into the thigh or abdomen. Some conditions begin with larger starting doses and then move to every-other-week or weekly dosing.

  • Rotate injection sites and avoid skin that is tender, bruised, red or hard.
  • You may let it sit out of the fridge for 15 to 30 minutes before injecting. Leave the cap on while it warms.
  • Check that the liquid is free of particles and discoloration.
  • It has no preservatives, so discard any unused portion.
  • If you miss a dose, take it as soon as possible, then return to your regular schedule.

Self-injection is allowed if your doctor agrees and you have been trained. Follow your prescriber and label.

Dosing details from the FDA-approved label

From the Adalimumab Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis (adults)
    • 40 mg every other week by subcutaneous injection
    • Some patients with RA not receiving methotrexate may benefit from increasing the dosage to 40 mg every week or 80 mg every other week
    • Increase applies to RA patients not taking concomitant MTX
  • Juvenile Idiopathic Arthritis, 2 years of age and older, 10 kg (22 lbs) to less than 15 kg (33 lbs)
    • 10 mg every other week
    • Weight-based dosing below 30 kg is only possible with the single-dose glass vial kit for institutional use only
  • Juvenile Idiopathic Arthritis, 2 years of age and older, 15 kg (33 lbs) to less than 30 kg (66 lbs)
    • 20 mg every other week
    • Weight-based dosing below 30 kg is only possible with the single-dose glass vial kit for institutional use only
  • Juvenile Idiopathic Arthritis, 2 years of age and older, 30 kg (66 lbs) and greater
    • 40 mg every other week
  • Crohn's Disease (adults)
    • 160 mg on Day 1 (given in one day or split over two consecutive days)
    • 80 mg on Day 15
    • 40 mg every other week starting on Day 29
  • Crohn's Disease, pediatric patients 6 years and older, 17 kg (37 lbs) to less than 40 kg (88 lbs)
    • Day 1: 80 mg
    • Day 15: 40 mg
    • 20 mg every other week starting on Day 29
    • Weight-based dosing below 40 kg is only possible with the single-dose glass vial kit for institutional use only
  • Crohn's Disease, pediatric patients 6 years and older, 40 kg (88 lbs) and greater
    • Day 1: 160 mg (single dose or split over two consecutive days)
    • Day 15: 80 mg
    • 40 mg every other week starting on Day 29
  • Ulcerative Colitis (adults)
    • 160 mg on Day 1 (given in one day or split over two consecutive days), 80 mg on Day 15 and 40 mg every other week starting on Day 29
    • Discontinue in patients without evidence of clinical remission by eight weeks (Day 57)
  • Plaque Psoriasis or Adult Uveitis (adults)
    • 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose
  • Hidradenitis Suppurativa (adults)
    • Day 1: 160 mg (given in one day or split over two consecutive days)
    • Day 15: 80 mg
    • Day 29 and subsequent doses: 40 mg every week or 80 mg every other week
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Administer by subcutaneous injection ( 2 ) Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis ( 2.1 ): Adults: 40 mg every other week. Some patients with RA not receiving methotrexate may benefit from increasing the dosage to 40 mg every week or 80 mg every other week. Juvenile Idiopathic Arthritis ( 2.2 ): Pediatric Weight 2 Years of Age and Older Recommended Dosage 10 kg (22 lbs) to less than 15 kg (33 lbs) 10 mg every other week 15 kg (33 lbs) to less than 30 kg (66 lbs) 20 mg every other week 30 kg (66 lbs) and greater 40 mg every other week Crohn's Disease ( 2.3 ): Adults: 160 mg on Day 1 (given in one day or split over two consecutive days); 80 mg on Day 15; and 40 mg every other week starting on Day 29. Pediatric Patients 6 Years of Age and Older : Pediatric Weight Recommended Dosage Days 1 and 15 Starting on Day 29 17 kg (37 lbs) to less than 40 kg (88 lbs) Day 1: 80 mg Day 15: 40 mg 20 mg every other week 40 kg (88 lbs) and greater Day 1: 160 mg (single dose or split over two consecutive days) Day 15: 80 mg 40 mg every other week Ulcerative Colitis ( 2.4 ): Adults: 160 mg on Day 1 (given in one day or split over two consecutive days), 80 mg on Day 15 and 40 mg every other week starting on Day 29. Discontinue in patients without evidence of clinical remission by eight weeks (Day 57). Plaque Psoriasis or Adult Uveitis ( 2.5 ): Adults: 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose. Hidradenitis Suppurativa ( 2.6 ): Adults: Day 1: 160 mg (given in one day or split over two consecutive days) Day 15: 80 mg Day 29 and subsequent doses: 40 mg every week or 80 mg every other week 2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis The recommended subcutaneous dosage of Adalimumab-aacf for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other week. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti- inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with Adalimumab-aacf. In the treatment of RA, some patients not taking concomitant MTX may derive additional benefit from increasing the dosage of Adalimumab-aacf to 40 mg every week or 80 mg every other week.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Adalimumab Injection side effects

▾

The most common side effects are:

Common side effects

  • Injection site reactions (redness, itching, pain, swelling, bleeding)
  • Upper respiratory infections and sinusitis
  • Headache
  • Rash
  • Nausea
  • Abdominal pain
  • Urinary tract infection
  • Back pain

When to get medical help

  • Get medical help right away for signs of infection such as fever, chills, cough or feeling very ill. Serious infections can lead to hospitalization or death.
  • Call your doctor if you have symptoms that could mean tuberculosis, even if your earlier TB test was negative.
  • Seek emergency care for signs of a serious allergic reaction (anaphylaxis) or swelling of the face or throat.
  • Tell your doctor about new or worsening heart failure symptoms.
  • Report new nerve or vision problems, as demyelinating disease (nerve-covering damage) can start or worsen.
  • Seek prompt care for unusual bruising, bleeding or paleness, which can signal low blood cell counts.
  • Tell your doctor if you develop a lupus-like illness.
  • If you carry hepatitis B, report any signs of liver problems or reactivation.

Adalimumab Injection warnings and precautions

▾
  • Serious infections, including tuberculosis, fungal and opportunistic infections, can be fatal. Do not start during an active infection.
  • Cancer risk: lymphoma and other cancers have been reported, including in children and young adults. Skin cancer checks are advised.
  • Serious allergic reactions can occur.
  • Hepatitis B can reactivate in carriers.
  • Nerve (demyelinating) disease, low blood counts, worsening heart failure and lupus-like illness can occur.

Adalimumab Injection interactions

▾

Several medicines can raise risk when combined with adalimumab.

  • Abatacept or anakinra: higher serious infection risk.
  • Other TNF blockers and biologic DMARDs: more infection risk, not recommended.
  • Live vaccines: avoid.
  • Azathioprine or 6-mercaptopurine: rare lymphoma concern.
  • Warfarin, cyclosporine, theophylline: levels or effect may change, so monitoring is advised.

Interactions listed in the FDA-approved label

From the Adalimumab Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Abatacept: Increased risk of serious infection with TNF blockers combined with abatacept, with no added benefit. Use with abatacept is not recommended in patients with RA.
  • Anakinra: Increased risk of serious infection with TNF blockers combined with anakinra, with no added benefit. Use with anakinra is not recommended in patients with RA.
  • Live vaccines: The label lists live vaccines as an interaction to avoid. Avoid the use of live vaccines with Adalimumab-aacf.
  • Methotrexate: MTX reduced the apparent adalimumab clearance in RA patients. The data do not suggest the need for dose adjustment of either Adalimumab-aacf or MTX.
  • Rituximab: A higher rate of serious infections was observed in RA patients treated with rituximab who received subsequent treatment with a TNF blocker.
  • Other biologic DMARDs or other TNF blockers: Possible increased risk for infections and other potential pharmacological interactions; insufficient information on concomitant use with other biologic products. Concomitant administration is not recommended.
  • Cytochrome P450 substrates with a narrow therapeutic index (e.g., warfarin, cyclosporine, theophylline): Adalimumab products may influence the formation of CYP450 enzymes by antagonizing cytokine activity. On initiation or discontinuation of Adalimumab-aacf, monitor the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline); the dose of the drug may be adjusted as needed.
Read the label’s full interactions text

7 DRUG INTERACTIONS Abatacept: Increased risk of serious infection. ( 5.1 , 5.11 , 7.2 ) Anakinra: Increased risk of serious infection. ( 5.1 , 5.7 , 7.2 ) Live vaccines: Avoid use with Adalimumab-aacf. ( 5.10 , 7.3 ) 7.1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either Adalimumab-aacf or MTX [see Clinical Pharmacology ( 12.3 )] . 7.2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of Adalimumab-aacf with abatacept or anakinra is not recommended in patients with RA [see Warnings and Precautions ( 5.7 , 5.11 )] . A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocker. There is insufficient information regarding the concomitant use of Adalimumab-aacf and other biologic products for the treatment of RA, PsA, AS, CD, UC, Ps, HS and UV. Concomitant administration of Adalimumab-aacf with other biologic DMARDS (e.g., anakinra and abatacept) or other TNF blockers is not recommended based upon the possible increased risk for infections and other potential pharmacological interactions. 7.3 Live Vaccines Avoid the use of live vaccines with Adalimumab-aacf [see Warnings and Precautions ( 5.10 )] . 7.4 Cytochrome P450 Substrates The formation of CYP450 enzymes may be suppressed by increased concentrations of cytokines (e.g., TNFα, IL-6) during chronic inflammation. It is possible for products that antagonize cytokine activity, such as adalimumab products, to influence the formation of CYP450 enzymes.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿53 supplements and herbs with documented Adalimumab Injection interactions, ranked by severity Check Adalimumab Injection against a supplement or herb →

Before taking Adalimumab Injection

▾
  • Tell your doctor about any current, chronic or recurring infection.
  • Get TB testing before starting and periodically after.
  • Mention hepatitis B, past cancer, heart failure, nerve disease or blood disorders.
  • Adults 65 and older may be at higher infection risk.
  • Discuss pregnancy: adalimumab crosses the placenta, and live vaccines for exposed infants need careful consideration.
  • Discuss breastfeeding: low amounts pass into milk.

Adalimumab Injection overdose

▾

Doses up to 10 mg/kg were given in trials without dose-limiting toxicity. After an overdose, the person should be watched for side effects and treated for symptoms. Consider calling Poison Help at 1-800-222-1222.

What Adalimumab Injection does in the body

▾

Treatment lowers inflammation markers such as C-reactive protein (CRP) and ESR in rheumatoid arthritis, and CRP in Crohn's disease, ulcerative colitis and hidradenitis suppurativa. It also lowers enzymes linked to cartilage breakdown.

How your body processes Adalimumab Injection

▾

After an injection under the skin, about 64% of the drug reaches the bloodstream, peaking in roughly 5 days. The half-life is about 2 weeks. Methotrexate can slightly slow its clearance, and antibodies against adalimumab can lower drug levels.

How to store Adalimumab Injection

▾

Do not use beyond the expiration date on the container. refrigerated at 36°F to 46°F (2°C to 8°C). DO NOT FREEZE.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

53

Supplements & herbs that interact with Adalimumab Injection

53 supplements and herbal products have documented interactions with Adalimumab Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Moderate · 52
  • Minor · 1
ACTIVE HEXOSE CORRELATED COMPOUND (AHCC) Moderate ALFALFA Moderate AMERICAN GINSENG Moderate ANDROGRAPHIS Moderate ASHWAGANDHA Moderate ASTRAGALUS Moderate BEE VENOM Moderate BETA-GLUCANS Moderate +45 more
Every supplement checked against Adalimumab Injection — ranked by severity The full interaction hub: 52 moderate · 1 minor · every one linked to its full report. Check Adalimumab Injection against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Adalimumab Injection: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Adalimumab Injection — the kind of thing our pharmacy team would talk through with you at the counter.

What is this medicine for?

▾
It calms inflammation in conditions like rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis. Which one applies to you depends on your diagnosis and the product you were prescribed.

How do I inject it?

▾
It goes under the skin of your thigh or abdomen. Rotate sites and avoid tender, bruised or red skin. You can let it warm up for 15 to 30 minutes first, with the cap on. If you miss a dose, take it as soon as you remember and then go back to your normal schedule.

What side effects should I expect?

▾
Injection site redness, itching or pain is the most common. Colds, sinus infections, headache and rash are also common. These are usually mild.

When should I call my doctor?

▾
Call right away for fever, chills, cough or any sign of infection, since serious infections can happen. Also call for signs of allergic reaction, new nerve or vision problems, unusual bruising or paleness, or worsening heart failure symptoms.

Do I need any tests or vaccines first?

▾
Yes, you need a TB test before starting and periodically after. Avoid live vaccines while taking it. Tell your doctor if you carry hepatitis B.

Is it safe in pregnancy?

▾
Studies can't clearly say whether it causes birth defects. It crosses the placenta late in pregnancy, so tell your doctor if you are pregnant or planning to be. Babies exposed in the womb need a doctor's guidance before getting live vaccines.

Is Adalimumab Injection available over the counter?

▾
No. Adalimumab Injection is a prescription medicine: every Adalimumab Injection product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Adalimumab Injection first available?

▾
The earliest FDA record we hold for Adalimumab Injection is from 2002: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Adalimumab Injection was first used.

Who makes Adalimumab Injection?

▾
2 companies currently list Adalimumab Injection products in the FDA's NDC Directory, including Fresenius Kabi USA, LLC, CELLTRION USA, Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Adalimumab Injection on HelloPharmacist

📊Adalimumab Injection supplement interactions53 checked — ranked by severity 🌿Drug & Supplement CheckerAdalimumab Injection vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Adalimumab Injection NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Adalimumab Injection Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Adalimumab Injection forms and strengths (how it comes)

Adalimumab Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Injection

By injection · Under the skin
Brands Idacio Yuflyma
How this form is used
What it may be used for
  • Yuflyma is established in children for polyarticular juvenile idiopathic arthritis (2 and older), Crohn's disease (6 and older) and uveitis (2 and older).
  • Yuflyma is also established for hidradenitis suppurativa in patients 12 and older.
Important instructions
  • Idacio has a single-dose glass vial kit for use in a hospital, office or clinic only, which allows weight-based dosing for children under 30 kg with JIA and under 40 kg with Crohn's disease.
Available strengths 6 strengths
20 mg/0.4 mL 40 mg/0.4 mL 40 mg/0.8 mL 50 mg/mL 80 mg/0.8 mL 100 mg/mL
15 FDA-listed product records ⓘ

Adalimumab Injection on the U.S. market: products, makers and brands

How Adalimumab Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

2 companies list 5 Adalimumab Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2002. Brand names on the directory include Humira, Amjevita, Yuflyma and 9 more; the rest are generics.

1
Dose forms ⓘ
2
Labelers (makers, repackagers, distributors)
3
Brand names
5
FDA-listed product records ⓘ
2002
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Kit (3) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Fresenius Kabi USA, LLC60%
CELLTRION USA, Inc.40%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Adalimumab Injection is used (Medicaid data)

A general measure of how commonly Adalimumab Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Adalimumab Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

478,866
Medicaid prescriptions filled (Q1–Q4 2025)
$3.6B gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Adalimumab Injection prescribed? Of the 1,601 medications we measure, Adalimumab Injection ranks #268 by Medicaid prescriptions — more than 83% of them.

Where Adalimumab Injection ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #268 of 1,601
#263 Mometasone Topical 494,371 Rx #264 Rimegepant 492,967 Rx #265 Phenazopyridine 491,698 Rx #266 Ofloxacin Ophthalmic 488,232 Rx #267 Buprenorphine Injectio... 481,260 Rx #268 Adalimumab Injection 478,866 Rx #269 Terbinafine 478,667 Rx #270 Levofloxacin 474,527 Rx #271 Nortriptyline 455,288 Rx #272 Carbamazepine 452,754 Rx #273 Penicillin V Potassium 451,965 Rx

Utilization by Adalimumab Injection product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 0.4 mL / 100 mg/mL auto-injector is the most-dispensed Adalimumab Injection product — about 57% of these Medicaid prescriptions.

0.4 ML adalimumab 100 MG/ML Auto-Injector Most dispensed

273,175 Medicaid prescriptions (Q1–Q4 2025) 57% of Adalimumab Injection prescriptions shown $2.27B gross reimbursement (before rebates) ≈ $8,294 per prescription (gross)

Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1872979

0.4 ML adalimumab-bwwd 100 MG/ML Auto-Injector

38,858 Medicaid prescriptions (Q1–Q4 2025) 8% of Adalimumab Injection prescriptions shown $49M gross reimbursement (before rebates) ≈ $1,260 per prescription (gross)

Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2640430

0.8 ML adalimumab 100 MG/ML Auto-Injector

38,338 Medicaid prescriptions (Q1–Q4 2025) 8% of Adalimumab Injection prescriptions shown $564.2M gross reimbursement (before rebates) ≈ $14,715 per prescription (gross)

Summed across the 1 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1921238

0.8 ML adalimumab 50 MG/ML Auto-Injector

26,817 Medicaid prescriptions (Q1–Q4 2025) 6% of Adalimumab Injection prescriptions shown $215.7M gross reimbursement (before rebates) ≈ $8,045 per prescription (gross)

Summed across the 1 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1655726

0.4 ML adalimumab 100 MG/ML Prefilled Syringe

21,231 Medicaid prescriptions (Q1–Q4 2025) 4% of Adalimumab Injection prescriptions shown $178.6M gross reimbursement (before rebates) ≈ $8,414 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1726844

0.4 ML adalimumab-ryvk 100 MG/ML Auto-Injector

13,695 Medicaid prescriptions (Q1–Q4 2025) 3% of Adalimumab Injection prescriptions shown $17.8M gross reimbursement (before rebates) ≈ $1,299 per prescription (gross)

Summed across the 2 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2677780

0.4 ML adalimumab-adaz 100 MG/ML Auto-Injector

13,576 Medicaid prescriptions (Q1–Q4 2025) 3% of Adalimumab Injection prescriptions shown $22.9M gross reimbursement (before rebates) ≈ $1,686 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2641655

0.4 ML adalimumab-atto 100 MG/ML Auto-Injector

8,248 Medicaid prescriptions (Q1–Q4 2025) 2% of Adalimumab Injection prescriptions shown $13.2M gross reimbursement (before rebates) ≈ $1,598 per prescription (gross)

Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2663908

0.8 ML adalimumab 50 MG/ML Prefilled Syringe

6,623 Medicaid prescriptions (Q1–Q4 2025) 1% of Adalimumab Injection prescriptions shown $52.1M gross reimbursement (before rebates) ≈ $7,866 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 727703

0.2 ML adalimumab 100 MG/ML Prefilled Syringe

6,161 Medicaid prescriptions (Q1–Q4 2025) 1% of Adalimumab Injection prescriptions shown $45.9M gross reimbursement (before rebates) ≈ $7,450 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1921016

0.4 ML adalimumab-adbm 100 MG/ML Auto-Injector

3,737 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $11M gross reimbursement (before rebates) ≈ $2,949 per prescription (gross)

Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2680748

0.8 ML adalimumab-bwwd 50 MG/ML Auto-Injector

3,726 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $4.9M gross reimbursement (before rebates) ≈ $1,308 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2640287

0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector

2,116 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $2.6M gross reimbursement (before rebates) ≈ $1,228 per prescription (gross)

Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2640404

0.8 ML adalimumab-bwwd 50 MG/ML Prefilled Syringe

1,255 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $1.5M gross reimbursement (before rebates) ≈ $1,192 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2640302

0.8 ML adalimumab-adaz 100 MG/ML Auto-Injector

739 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $2.2M gross reimbursement (before rebates) ≈ $2,966 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2641662

0.8 ML adalimumab-atto 100 MG/ML Auto-Injector

684 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $1.9M gross reimbursement (before rebates) ≈ $2,793 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2663914

0.4 ML adalimumab-adaz 100 MG/ML Prefilled Syringe

639 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $935,299 gross reimbursement (before rebates) ≈ $1,464 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2641660

0.8 ML adalimumab-adbm 50 MG/ML Auto-Injector

601 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $1.9M gross reimbursement (before rebates) ≈ $3,107 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2640895

0.4 ML adalimumab-ryvk 100 MG/ML Prefilled Syringe

574 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $795,569 gross reimbursement (before rebates) ≈ $1,386 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2688826

0.8 ML adalimumab-aacf 50 MG/ML Auto-Injector

562 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $604,850 gross reimbursement (before rebates) ≈ $1,076 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2640859

0.4 ML adalimumab-atto 100 MG/ML Prefilled Syringe

553 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $929,704 gross reimbursement (before rebates) ≈ $1,681 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2663906

0.8 ML adalimumab-ryvk 100 MG/ML Auto-Injector

530 Medicaid prescriptions (Q2–Q4 2025) <1% of Adalimumab Injection prescriptions shown $1.3M gross reimbursement (before rebates) ≈ $2,469 per prescription (gross)

Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2706644

0.1 ML adalimumab 100 MG/ML Prefilled Syringe

526 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $3.7M gross reimbursement (before rebates) ≈ $6,975 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1921009

0.8 ML adalimumab-aqvh 50 MG/ML Auto-Injector

493 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $580,548 gross reimbursement (before rebates) ≈ $1,178 per prescription (gross)

Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2640397

0.2 ML adalimumab-atto 100 MG/ML Prefilled Syringe

170 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $317,181 gross reimbursement (before rebates) ≈ $1,866 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2663901

0.2 ML adalimumab-adaz 100 MG/ML Prefilled Syringe

161 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $216,157 gross reimbursement (before rebates) ≈ $1,343 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2641653

0.4 ML adalimumab-adbm 100 MG/ML Prefilled Syringe

142 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $347,074 gross reimbursement (before rebates) ≈ $2,444 per prescription (gross)

Summed across the 2 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2680743

0.2 ML adalimumab-ryvk 100 MG/ML Prefilled Syringe

105 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $109,603 gross reimbursement (before rebates) ≈ $1,044 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2688819

0.8 ML adalimumab-atto 50 MG/ML Auto-Injector

104 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $389,119 gross reimbursement (before rebates) ≈ $3,742 per prescription (gross)

Summed across the 1 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2627719

0.4 ML adalimumab-adbm 50 MG/ML Prefilled Syringe

97 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $125,356 gross reimbursement (before rebates) ≈ $1,292 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2640893

0.8 ML adalimumab-adbm 50 MG/ML Prefilled Syringe

78 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $96,792 gross reimbursement (before rebates) ≈ $1,241 per prescription (gross)

Summed across the 1 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2640883

0.8 ML adalimumab-fkjp 50 MG/ML Prefilled Syringe

51 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $56,396 gross reimbursement (before rebates) ≈ $1,106 per prescription (gross)

Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2640417

0.4 ML adalimumab-fkjp 50 MG/ML Prefilled Syringe

28 Medicaid prescriptions (Q1–Q4 2025) <1% of Adalimumab Injection prescriptions shown $30,899 gross reimbursement (before rebates) ≈ $1,104 per prescription (gross)

Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2640412

Other Adalimumab Injection products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)

14,473 Medicaid prescriptions (Q1–Q4 2025) 3% of Adalimumab Injection prescriptions shown $137.7M gross reimbursement (before rebates) ≈ $9,513 per prescription (gross)

Summed across the 11 of 117 listed NDC products with Medicaid activity.

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Adalimumab Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 55 of 281 listed Adalimumab Injection NDCs with Medicaid activity.

Compare Adalimumab Injection products

A representative set of FDA-listed product records for Adalimumab Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
40 mg/0.4 mL Subcutaneous CELLTRION USA, Inc. BLA View NDC →
80 mg/0.8 mL Subcutaneous CELLTRION USA, Inc. BLA View NDC →
40 mg/0.8 mL Subcutaneous Fresenius Kabi USA, LLC BLA View NDC →
💊Kits
— Subcutaneous Fresenius Kabi USA, LLC × 2 listings BLA View NDC →

Showing 5 of 5 products — FDA National Drug Code Directory. See every product, package size and price: browse all 5 Adalimumab Injection NDCs →

Adalimumab Injection recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Adalimumab recalls since July 2021.

✅No Adalimumab recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Adalimumab Injection RxCUI 327361 3 dose forms · 57 strengths
  1. Dose form (SCDF) Auto-Injector RxCUI 1655725 In current FDA listings
    Clinical drug / strength (SCD) 0.4 ML adalimumab 100 MG/ML RxCUI 1872979 0.4 ML adalimumab-aaty 100 MG/ML RxCUI 2639651 0.4 ML adalimumab-adaz 100 MG/ML RxCUI 2641655 0.4 ML adalimumab-adbm 100 MG/ML RxCUI 2680748 0.4 ML adalimumab-atto 100 MG/ML RxCUI 2663908 0.4 ML adalimumab-bwwd 100 MG/ML RxCUI 2640430 0.4 ML adalimumab-ryvk 100 MG/ML RxCUI 2677780 0.8 ML adalimumab 100 MG/ML RxCUI 1921238 0.8 ML adalimumab 50 MG/ML RxCUI 1655726 0.8 ML adalimumab-aacf 50 MG/ML RxCUI 2640859 0.8 ML adalimumab-aaty 100 MG/ML RxCUI 2668487 0.8 ML adalimumab-adaz 100 MG/ML RxCUI 2641662 0.8 ML adalimumab-adaz 50 MG/ML RxCUI 2665419 0.8 ML adalimumab-adbm 50 MG/ML RxCUI 2640895 0.8 ML adalimumab-afzb 50 MG/ML RxCUI 2668064 0.8 ML adalimumab-aqvh 50 MG/ML RxCUI 2640397 0.8 ML adalimumab-atto 100 MG/ML RxCUI 2663914 0.8 ML adalimumab-atto 50 MG/ML RxCUI 2627719 0.8 ML adalimumab-bwwd 50 MG/ML RxCUI 2640287 0.8 ML adalimumab-fkjp 50 MG/ML RxCUI 2640404 0.8 ML adalimumab-ryvk 100 MG/ML RxCUI 2706644
  2. Dose form (SCDF) Injection RxCUI 1656695 In current FDA listings
    Clinical drug / strength (SCD) 0.8 ML adalimumab-aacf 50 MG/ML RxCUI 2699315 0.8 ML adalimumab-bwwd 50 MG/ML RxCUI 2640419
  3. Dose form (SCDF) Prefilled Syringe RxCUI 727702 No current FDA listing
    Clinical drug / strength (SCD) 0.1 ML adalimumab 100 MG/ML RxCUI 1921009 0.1 ML adalimumab-adaz 100 MG/ML RxCUI 2641644 0.2 ML adalimumab 100 MG/ML RxCUI 1921016 0.2 ML adalimumab-aaty 100 MG/ML RxCUI 2668483 0.2 ML adalimumab-adaz 100 MG/ML RxCUI 2641653 0.2 ML adalimumab-adbm 50 MG/ML RxCUI 2640891 0.2 ML adalimumab-atto 100 MG/ML RxCUI 2663901 0.2 ML adalimumab-atto 50 MG/ML RxCUI 2634478 0.2 ML adalimumab-ryvk 100 MG/ML RxCUI 2688819 0.4 ML adalimumab 100 MG/ML RxCUI 1726844 0.4 ML adalimumab-aaty 100 MG/ML RxCUI 2639659 0.4 ML adalimumab-adaz 100 MG/ML RxCUI 2641660 0.4 ML adalimumab-adbm 100 MG/ML RxCUI 2680743 0.4 ML adalimumab-adbm 50 MG/ML RxCUI 2640893 0.4 ML adalimumab-afzb 50 MG/ML RxCUI 2668095 0.4 ML adalimumab-atto 100 MG/ML RxCUI 2663906 0.4 ML adalimumab-atto 50 MG/ML RxCUI 2627711 0.4 ML adalimumab-bwwd 100 MG/ML RxCUI 2640425 0.4 ML adalimumab-fkjp 50 MG/ML RxCUI 2640412 0.4 ML adalimumab-ryvk 100 MG/ML RxCUI 2688826 0.8 ML adalimumab 100 MG/ML RxCUI 1855523 0.8 ML adalimumab 50 MG/ML RxCUI 727703 0.8 ML adalimumab-aacf 50 MG/ML RxCUI 2640851 0.8 ML adalimumab-aaty 100 MG/ML RxCUI 2668485 0.8 ML adalimumab-adaz 100 MG/ML RxCUI 2641666 0.8 ML adalimumab-adaz 50 MG/ML RxCUI 2665424 0.8 ML adalimumab-adbm 50 MG/ML RxCUI 2640883 0.8 ML adalimumab-afzb 50 MG/ML RxCUI 2668074 0.8 ML adalimumab-aqvh 50 MG/ML RxCUI 2640389 0.8 ML adalimumab-atto 100 MG/ML RxCUI 2663912 0.8 ML adalimumab-atto 50 MG/ML RxCUI 2627724 0.8 ML adalimumab-bwwd 50 MG/ML RxCUI 2640302 0.8 ML adalimumab-fkjp 50 MG/ML RxCUI 2640417 0.8 ML adalimumab-ryvk 100 MG/ML RxCUI 2688828

Look up RxCUI 327361 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Adalimumab Injection costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Injection · Subcutaneous 40 mg/0.4 mL $896.84–$912.21 each NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Adalimumab Injection brand names

Adalimumab Injection is sold under 12 brand names in the FDA directory — Humira, Amjevita, Yuflyma, Hadlima and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Humira Amjevita Yuflyma Hadlima Yusimry Hulio Idacio Cyltezo Hyrimoz Abrilada Simlandi Adalimumab-aacf

Who makes Adalimumab Injection: manufacturers and labelers

2 companies list Adalimumab Injection products with the FDA. By number of product records, the largest are Fresenius Kabi USA, LLC, CELLTRION USA, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Fresenius Kabi USA, LLC 3 CELLTRION USA, Inc. 2

Adalimumab Injection drug class (RxNorm)

Adalimumab Injection belongs to the Tumor Necrosis Factor Blocker class.

Pharmacologic class Tumor Necrosis Factor Blocker
Drug family (ATC) Tumor necrosis factor alpha (TNF-alpha) inhibitors
How it works Tumor Necrosis Factor Receptor Blocking Activity

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Adalimumab Injection page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jan 8, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Adalimumab Injection.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Adalimumab Injection after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
3
Finished products in the current FDA directory
5
Companies listing them (makers, repackagers, distributors)
2
FDA labeler codes behind them ⓘ
2
Linked representative label ⓘ
Fresenius Kabi USA, LLC
Linked label effective
Jan 8, 2026
Composite sections available
26
Linked SPL Set ID
2488b0bc-7b8f-4cc8-91ea-48e7ea5e8915
Linked SPL Document ID
ed59e023-eb91-482f-a1fe-19a31c0906c2
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Fresenius Kabi USA, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →